skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Reversal of brain metabolic abnormalities following treatment of AIDS dementia complex with 3'-azido-2',3'-dideoxythymidine (AZT, zidovudine): a PET-FDG study

Abstract

Brain glucose metabolism was evaluated in four patients with acquired immunodeficiency syndrome (AIDS) dementia complex using (/sup 18/F)fluorodeoxyglucose (FDG) and positron emission tomography (PET) scans at the beginning of therapy with 3'-azido-2',3'-dideoxythymidine (AZT, zidovudine), and later in the course of therapy. In two patients, baseline, large focal cortical abnormalities of glucose utilization were reversed during the course of therapy. In the other two patients, the initial PET study did not reveal pronounced focal alterations, while the post-treatment scans showed markedly increased cortical glucose metabolism. The improved cortical glucose utilization was accompanied in all patients by immunologic and neurologic improvement. PET-FDG studies can detect cortical metabolic abnormalities associated with AIDS dementia complex, and may be used to monitor the metabolic improvement in response to AZT treatment.

Authors:
; ; ; ; ; ; ; ; ;
Publication Date:
Research Org.:
NINCDS, Bethesda, MD (USA)
OSTI Identifier:
6028988
Alternate Identifier(s):
OSTI ID: 6028988
Resource Type:
Journal Article
Resource Relation:
Journal Name: J. Nucl. Med.; (United States); Journal Volume: 30:5
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; AIDS; CHEMOTHERAPY; BRAIN; RADIOISOTOPE SCANNING; GLUCOSE; METABOLISM; METABOLIC DISEASES; DIAGNOSIS; COLOR; FLUORINE 18; PATIENTS; POSITRON COMPUTED TOMOGRAPHY; ALDEHYDES; BETA DECAY RADIOISOTOPES; BETA-PLUS DECAY RADIOISOTOPES; BODY; CARBOHYDRATES; CENTRAL NERVOUS SYSTEM; COMPUTERIZED TOMOGRAPHY; COUNTING TECHNIQUES; DIAGNOSTIC TECHNIQUES; DISEASES; EMISSION COMPUTED TOMOGRAPHY; FLUORINE ISOTOPES; HEMIC DISEASES; HEXOSES; HOURS LIVING RADIOISOTOPES; IMMUNE SYSTEM DISEASES; INFECTIOUS DISEASES; ISOTOPES; LIGHT NUCLEI; MONOSACCHARIDES; NERVOUS SYSTEM; NUCLEI; ODD-ODD NUCLEI; OPTICAL PROPERTIES; ORGANIC COMPOUNDS; ORGANOLEPTIC PROPERTIES; ORGANS; PHYSICAL PROPERTIES; RADIOISOTOPES; SACCHARIDES; THERAPY; TOMOGRAPHY; VIRAL DISEASES 550601* -- Medicine-- Unsealed Radionuclides in Diagnostics

Citation Formats

Brunetti, A., Berg, G., Di Chiro, G., Cohen, R.M., Yarchoan, R., Pizzo, P.A., Broder, S., Eddy, J., Fulham, M.J., and Finn, R.D. Reversal of brain metabolic abnormalities following treatment of AIDS dementia complex with 3'-azido-2',3'-dideoxythymidine (AZT, zidovudine): a PET-FDG study. United States: N. p., 1989. Web.
Brunetti, A., Berg, G., Di Chiro, G., Cohen, R.M., Yarchoan, R., Pizzo, P.A., Broder, S., Eddy, J., Fulham, M.J., & Finn, R.D. Reversal of brain metabolic abnormalities following treatment of AIDS dementia complex with 3'-azido-2',3'-dideoxythymidine (AZT, zidovudine): a PET-FDG study. United States.
Brunetti, A., Berg, G., Di Chiro, G., Cohen, R.M., Yarchoan, R., Pizzo, P.A., Broder, S., Eddy, J., Fulham, M.J., and Finn, R.D. Mon . "Reversal of brain metabolic abnormalities following treatment of AIDS dementia complex with 3'-azido-2',3'-dideoxythymidine (AZT, zidovudine): a PET-FDG study". United States. doi:.
@article{osti_6028988,
title = {Reversal of brain metabolic abnormalities following treatment of AIDS dementia complex with 3'-azido-2',3'-dideoxythymidine (AZT, zidovudine): a PET-FDG study},
author = {Brunetti, A. and Berg, G. and Di Chiro, G. and Cohen, R.M. and Yarchoan, R. and Pizzo, P.A. and Broder, S. and Eddy, J. and Fulham, M.J. and Finn, R.D.},
abstractNote = {Brain glucose metabolism was evaluated in four patients with acquired immunodeficiency syndrome (AIDS) dementia complex using (/sup 18/F)fluorodeoxyglucose (FDG) and positron emission tomography (PET) scans at the beginning of therapy with 3'-azido-2',3'-dideoxythymidine (AZT, zidovudine), and later in the course of therapy. In two patients, baseline, large focal cortical abnormalities of glucose utilization were reversed during the course of therapy. In the other two patients, the initial PET study did not reveal pronounced focal alterations, while the post-treatment scans showed markedly increased cortical glucose metabolism. The improved cortical glucose utilization was accompanied in all patients by immunologic and neurologic improvement. PET-FDG studies can detect cortical metabolic abnormalities associated with AIDS dementia complex, and may be used to monitor the metabolic improvement in response to AZT treatment.},
doi = {},
journal = {J. Nucl. Med.; (United States)},
number = ,
volume = 30:5,
place = {United States},
year = {Mon May 01 00:00:00 EDT 1989},
month = {Mon May 01 00:00:00 EDT 1989}
}